Well Researched

Larazotide

Inflammation & Immunity · ['Larazotide acetate', 'AT-1001', 'INN-202', 'GGVLVQPG']

Larazotide is an investigational orally administered octapeptide studied as a tight-junction regulator (permeability modulator) of the intestinal epithelium, evaluated in celiac disease research.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.

Molecular Formula

C32H55N9O10

Molecular Weight

725.8 g/mol

PubChem

CID 9810532 ↗

Research Level

Well Researched

Browse the store →

Larazotide (larazotide acetate; development codes AT-1001 / INN-202) is an investigational synthetic octapeptide with the sequence GGVLVQPG. It has been studied as a regulator of intestinal epithelial tight junctions, a class often referred to in the literature as intestinal permeability modulators [1].

The peptide has been evaluated primarily in celiac disease research, including randomized clinical trials examining symptom and permeability-related endpoints in adults maintaining a gluten-free diet [2]. As an investigational agent it has not received general marketing authorization at the time of writing.

Because it acts locally in the gut lumen and is described as minimally absorbed, larazotide is studied as an orally administered peptide, distinguishing it from many systemically acting peptides.

Larazotide is reported to act at the intestinal epithelium, where the published mechanism describes stabilization of tight junctions and reduction of paracellular permeability associated with zonulin-related signaling [1]. This is characterized in the literature as counteracting increased intestinal permeability seen in certain inflammatory and autoimmune research contexts.

All mechanistic and effect descriptions are drawn from cited studies and characterize the peptide's biology, not outcomes for any individual.

Tight-junction regulation and intestinal paracellular permeability [1]
Celiac disease symptom endpoints in adults on a gluten-free diet [2]
Zonulin-pathway and epithelial-barrier signaling studies [1]
Intestinal inflammation and barrier-dysfunction models [3]
Pharmacokinetic characterization of a minimally absorbed oral peptide [2]

📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Phase 2b celiac disease trial: A randomized, double-blind, placebo-controlled trial evaluated larazotide acetate across dose groups in adults with celiac disease on a gluten-free diet, reporting change in gastrointestinal and non-gastrointestinal symptom scores versus placebo over the study period [2]. Reported here for scientific reference only.

Gluten-challenge permeability studies: Controlled research used gluten-challenge designs to assess larazotide's effect on intestinal permeability measures and symptom endpoints, reporting the protocol-defined outcomes [1].

Preclinical barrier-function studies: In vitro epithelial-monolayer and animal studies characterized the peptide's effect on tight-junction integrity and paracellular permeability [3].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

Gluten (dietary antigen challenge)Neutral

Used as the challenge stimulus in celiac permeability study designs [1].

Zonulin-pathway modulatorsCompatible

Same tight-junction/zonulin biology studied in barrier research.

Anti-inflammatory / immunosuppressive agentsNeutral

Co-studied in intestinal inflammation research contexts.

Orally administered small moleculesCaution

Altered permeability is a consideration when interpreting co-administration in barrier research.

What is larazotide's proposed mechanism?

Published studies describe it as a tight-junction regulator that reduces intestinal paracellular permeability, associated with zonulin-related signaling [1].

What is its amino acid sequence?

It is the octapeptide GGVLVQPG (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) [PubChem CID 9810532].

What has clinical research focused on?

Randomized trials have studied celiac disease symptom and permeability endpoints in adults on a gluten-free diet [2].

Is larazotide approved?

It is described as investigational and has not received general marketing authorization at the time of writing [2].

Can I use this product?

No. It is supplied for laboratory research use only and is not intended for human or veterinary use, nor to diagnose, treat, cure, or prevent any disease.

Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.